针对IDH1-突变性肝内胆瘤的伊沃西登尼:多中心实验研究的见解
Monica Niger1, Margherita Rimini2, Florian Castet3
1Medical Oncology Department, Fondazione IRCCS Instituto Nazionale dei Tumori di Milano, Milan, Italy.
概括
在初始治疗后,IVOSIDENIB对IDH1突变胆管癌 (CCA) 的治疗具有前景. 这项研究发现,与晚期CCA患者的化疗相比,IVOSIDENIB改善了无进展生存率和整体生存率.
科学领域:
- 癌症学
- 癌症治疗方法
- 基因组医学
背景情况:
- 胆管癌 (CCA) 具有有限的治疗选择和不良预后,特别是在晚期.
- 虽然一线治疗改善了结果,但二线治疗CCA仍然是一个重大的临床挑战.
- 一种向异酸脱酶1 (IDH1) 的抑制剂伊沃西代尼布显示了IDH1突变CCA的潜力,但实际证据很少.
研究的目的:
- 评估ivosidenib在大量IDH1突变CCA患者中的实际疗效和安全性.
- 在该患者群体中比较ivosidenib治疗与二线化疗的结果.
- 提供关于ivosidenib在转移IDH1突变CCA治疗中的作用的有价值的数据.
主要方法:
- 一项多中心的观察性回顾性研究,涉及11个欧洲机构的46名IDH1突变CCA患者.
- 评估ivosidenib的无进展生存 (PFS),整体生存 (OS),疾病控制率 (DCR) 和安全性.
- 使用治疗重量的逆概率 (IPTW) 进行探索性分析,以比较ivosidenib和FOLFOX/ CAPOX化疗之间的PFS和OS.
主要成果:
- 伊沃西登尼的PFS中位数为3. 7个月,OS为11. 5个月,其DCR为50. 0%.
- 在8. 7%的患者中观察到≥3级不良事件,表明可控的安全性.
- 与FOLFOX/ CAPOX相比,IPTW调整后的分析显示,IVOSIDENIB的中位数PFS (6. 9个月与2. 1个月) 和OS (15. 9个月与9. 0个月) 显著长.
结论:
- 对于已经过至少一次标准治疗的转移IDH1突变CCA患者来说,IVOSIDENIB是一种可行的治疗选择.
- 与传统化疗相比,该研究支持ivosidenib在该特定患者小组中改善生存结果的有效性.
- 实践数据证实了针对性治疗对像CCA这样的罕见癌症的治疗有潜力.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Clinical Trials
8.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.1K
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267


